Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AQ002&3P
- Development stage
- Preclinical
- Lead developer
- Aquilon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AQ002&3P is a small molecule combination therapy developed by Aquilon Pharmaceuticals for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It consists of an inhaled corticosteroid (ICS) and a long-acting beta-2 adrenergic agonist (LABA) reformulated using Aquilon's proprietary HPBetadex (hydroxypropyl-beta-cyclodextrin) excipient technology. This platform is designed to improve the solubility and delivery of existing respiratory drugs, potentially enhancing efficacy and patient outcomes. The drug exerts its therapeutic effect through the activation of the glucocorticoid receptor to reduce airway inflammation and the beta-2 adrenergic receptor to induce bronchodilation. It is intended for administration via a dry powder inhaler (DPI).
- Other names
- ICS-LABA combination
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on AQ002&3P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AQ002&3P.